International MedTech manufacturers, regulatory affairs managers, product managers, and marketing teams planning to enter the German or wider European market increasingly view Spain as a compelling strategic entry point. The country combines a large and aging population, a universal healthcare system, strong public investment, and a rapidly expanding digital‑health ecosystem. Spanish healthcare offers fertile ground for innovative medical technologies, particularly those addressing chronic disease management, diagnostic imaging, telemedicine, and AI‑driven solutions. Because Spain aligns fully with EU regulatory frameworks, market entry here supports broader European expansion.

Population and Disease Landscape

Spain’s population stands at roughly 48–49 million people, and more than 20% are aged 65 or older. This demographic shift places Spain among Europe’s oldest countries. Life expectancy remains high at around 83 years, which increases demand for long‑term care, chronic‑disease management, and advanced diagnostic technologies. Chronic diseases shape the country’s health profile. High cholesterol, hypertension, mental health disorders, lower back pain, osteoarthritis, and diabetes affect millions of people. Cardiovascular disease and cancer remain the leading causes of death. These patterns create sustained demand in the Spanish healthcare system for cardiovascular devices, oncology technologies, orthopedic solutions, and digital tools that support continuous monitoring.

Manufacturers entering Spain must understand these demographic realities. They also need to communicate them clearly in Spanish, using terminology familiar to clinicians and regional health authorities. Accurate translation of epidemiological data and clinical claims strengthens trust and supports evidence‑based decision‑making.

Structure of the Spanish Healthcare System

Spain operates a universal, tax‑funded national health system (SNS) that provides comprehensive coverage at the point of care. The Spanish healthcare system is highly decentralized. Autonomous communities manage healthcare delivery, while the Ministry of Health coordinates national policy and sets strategic priorities. Public expenditure accounts for more than 70% of total health spending. Out‑of‑pocket payments remain moderate and mainly cover dental, optical, and some pharmaceutical costs. Spain’s healthcare infrastructure includes hundreds of hospitals, thousands of primary‑care centers, and millions of annual consultations, including a growing share of teleconsultations.

The decentralized structure requires manufacturers to adapt communication and documentation to regional expectations. Some regions use co‑official languages such as Catalan, Basque, or Galician in healthcare settings. While Spanish remains the regulatory standard, localized materials often improve stakeholder engagement and support smoother procurement discussions.

Market Environment for Medical Technology and Pharmaceuticals

Spain’s MedTech sector continues to expand steadily. Recent analyses estimate the Spanish medical devices market at EUR 12.5–13 billion in 2024, with projections reaching EUR 13.8–14.2 billion in 2025. Long‑term forecasts expect the market to grow to EUR 25–27 billion by 2035, reflecting a compound annual growth rate of around 6%.

Diagnostic imaging remains the largest segment, driven by high demand for MRI, CT, and ultrasound technologies. Telehealth and remote‑monitoring solutions show the fastest growth in Spain, supported by digitization efforts and rising chronic‑care needs. Spain’s strong public investment reinforces this momentum. Healthcare spending exceeded 7.5% of GDP in 2025, which accelerated the procurement of advanced diagnostic and therapeutic devices. Spain hosts more than 5,000 MedTech companies, employing roughly 32,000 professionals. This confirms the country’s role as one of Europe’s most dynamic healthcare markets. International manufacturers benefit from Spain’s appetite for innovation, but they must present their value propositions in clear, localized Spanish. Clinicians and procurement officers expect precise terminology, culturally adapted messaging, and documentation that aligns with Spanish clinical practice.

Trends

The Spanish healthcare system is undergoing a rapid digital transformation. Telemedicine adoption surged in recent years, especially after natural disasters and public‑health pressures highlighted the need for remote‑care continuity. Health‑technology companies expanded virtual‑care offerings, particularly in tourist regions where seasonal population spikes strain local systems. Wearables and mobile health apps continue to gain traction. High smartphone penetration and growing health awareness support this trend. AI integration accelerates across diagnostics, patient management, and personalized medicine. The government invests heavily in digital infrastructure and supports startups that develop AI‑driven clinical tools.

Complementary therapies maintain cultural relevance, but digital health and evidence‑based technologies dominate investment priorities. Manufacturers entering this space must localize digital interfaces, patient instructions, and clinical dashboards. Spanish users expect intuitive, culturally adapted language, especially older patients who rely on clear guidance to use digital tools safely. The growing non-Spanish speaking population expects the same, specifically the high number of expat retirees, which hail mostly from Germany, the UK, and recently growing numbers from the US. Additionally, and due to the high migration numbers of recent years, there is a high influx of Arabic-speaking residents.

Importance for Manufacturers

The Spanish healthcare system offers several strategic advantages for international MedTech manufacturers. An aging population and chronic‑disease burden create consistent demand for advanced diagnostics, monitoring devices, and minimally invasive technologies. The universal healthcare system ensures predictable reimbursement pathways and stable procurement cycles. The country’s digital‑health momentum opens opportunities for AI‑enabled devices, telehealth platforms, and remote‑monitoring solutions. Spain also serves as a valuable test market for broader EU expansion. Manufacturers can pilot solutions regionally before scaling nationally or entering Germany and other EU countries. Spain’s alignment with EU regulations ensures that devices approved here transition smoothly across the European market.

Translation and localization amplify these advantages. Spanish clinicians value clarity and precision. Regulatory authorities expect accurate, compliant documentation. And, of course: Patients respond better to localized instructions and user interfaces. Manufacturers who invest in high‑quality localization improve safety, reduce user errors, and strengthen their market position.

Legal and regulatory conditions

Spain follows the EU Medical Device Regulation (MDR 2017/745) and the In Vitro Diagnostic Regulation (IVDR 2017/746). These frameworks classify devices by risk and require rigorous pre‑ and post‑market controls. Manufacturers must work with EU‑authorized notified bodies for conformity assessment. The Spanish Agency of Medicines and Medical Devices (AEMPS) enforces compliance and oversees market surveillance.

And because Spain fully adheres to EU regulations, market entry here supports broader European compliance strategies. However, manufacturers must provide all labeling, packaging, and instructions in Spanish. MDR and IVDR require linguistic accuracy, and AEMPS expects clear, consistent terminology. Poor translation can delay approvals or trigger corrective actions.

The Road to Success

Manufacturers vying for a slice of the Spanish healthcare pie should adopt a phased, evidence‑driven approach. They should begin by mapping regional healthcare priorities, since autonomous communities control procurement and may differ in digital‑health readiness or specialty‑care needs. Early engagement with clinical stakeholders builds trust and supports smoother adoption. Like anywhere else, local partnerships strengthen market entry. Collaborations with Spanish research institutes, for example the Carlos III Health Institute, support clinical validation and accelerate acceptance. Manufacturers should also emphasize interoperability with Spain’s expanding telehealth and electronic‑health‑record systems.

Bottom Line

Spain stands out as a high‑potential market for international MedTech manufacturers aiming to enter Germany or the wider European region. Its universal healthcare system, aging population, strong digital‑health momentum, and alignment with EU regulations create a fertile environment for innovative medical technologies. Manufacturers who understand Spain’s regional dynamics, regulatory landscape, and clinical priorities — and who invest in high‑quality translation and localization — can establish a strong foothold that supports long‑term European expansion.

Sources

 

autor_eurotext_100Author: Eurotext Editorial Team

We explain how internationalization works, provide tips for your translation projects and outline some of the technology and processes used. We also report on current e-commerce developments and cover a range of language-related topics.